Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 10 Neuroendocrine Tumors 6 Gastro-enteropancreatic neuroendocrine tumor 3 Neoplasms by Histologic Type 2 Neoplasms 2 Digestive System Neoplasms 2 Urogenital Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Prostatic Diseases 1 Prostate Cancer Metastatic 1 Pheochromocytoma 1 Paraganglioma 1 Pancreatic Neoplasms 1 Pancreatic Diseases 1 Oligometastatic Prostate Cancer (OMPC) 1 Neuroectodermal Tumors 1 Neoplasms, Nerve Tissue 1 Neoplasms, Germ Cell and Embryonal 1 Neoplasms by Site 1 Neoplasm Metastasis 1 Metastatic Neuroendocrine Prostate Cancer 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Metastatic Castration-Resistant Prostate Cancer 1 Metastatic Castration Resistant Prostate Cancer (mCRPC) 1 Lymphoproliferative Disorders 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1

Interventions

vandetanib 14 cabozantinib 9 selpercatinib 6 Sorafenib 5 Everolimus 5 pralsetinib 3 Magnetic Resonance Spectroscopy 3 Capecitabine 3 sargramostim 2 lutetium Lu 177 dotatate 2 lenvatinib 2 Trastuzumab 2 Thyroidectomy 2 Temozolomide 2 Sunitinib 2 Specimen Handling 2 Octreotide 2 High-Energy Shock Waves 2 Gefitinib 2 Doxorubicin 2 yeast-CEA vaccine 1 veliparib 1 vatalanib 1 tumor necrosis factor-alpha, CNGRC fusion protein, human 1 tipifarnib 1 temsirolimus 1 tanespimycin 1 sacubitril and valsartan sodium hydrate drug combination 1 rovalpituzumab tesirine 1 ponatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Medullary × Lutetium-177 × Clear all

NCT01915485 2016-09-07

Radiolabeled Molecules for Medullary Thyroid Cancer

Instituto Nacional de Cancer, Brazil

Phase 4 Unknown

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡